2% of patients in trials had CKD stage 3b+ Subgroup status: Ejection fraction: Mixed NYHA class: Mixed (II-IV) Industry funded HEAAL trial: Konstam Angiotensin receptor antagonists. Losartan 150mg per day Angiotensin receptor antagonists. Losartan Duration median 4.7y N=945 patients with CKD Pre-specified subgroup analysis of multicentre study. HF: NYHA class II-IV, intolerant to ACE- inhibitors CKD subgroup: eGFR Hospitalisation Recruitment dates not reported. 20% of patients in trial had Subgroup status: Ejection fraction: All reduced NYHA class: Mixed, most class II Funded by industry SOLVD-treat trial: Bowling (Bohm ; SOLVD investigators ) Angiotensin converting enzyme (ACE) inhibitors. Enalapril 2.5 to Placebo Duration Mean 41 months N=1036 patients with CKD Post-hoc subgroup analysis of older trialb HF: LVEF <35% who were not currently receiving ACEIs CKD subgroup: Mortality Hospitalisation Renal function Hyperkalaemia Recruited 1986-89. 40% of patients in trial had CKD (10% Subgroup status: Ejection fraction: All reduced NYHA class: mixed Original study funded by industry, but this analysis was not VAL-HeFT trial: Anand (Lesogor ; Cohn ) Angiotensin receptor antagonists/blockers (ARB) Valsartan, target dose 160mg twice a day with creatinine and blood Post-hoc analysis of multicentre trial. HF: Stable, symptomatic HF, LVSD Mortality Hospitalisation Renal function Renal failure Hyperkalaemia Recruitment dates NK. 58% of patients in trial had CKD stage Subgroup status: Ejection fraction: All Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Study Intervention and comparison Population Outcomes Comments pressure monitoring Placebo with creatinine and blood pressure monitoring Duration 2y average (mean 23 months, range 0-38 months) on echo. On HF medication. CKD subgroup: subdivided by those with and without proteinuria) mostly stage 3, some early 4. reduced NYHA class: Mixed Funded by industry CIBIS-II trial: Castagno ) Intervention 1: Beta- blockers (BB). 